Farther Finance Advisors LLC Acquires 11,956 Shares of Merck & Co., Inc. $MRK

Key Points

• Farther Finance Advisors increased its Merck position by 9.9% in the third quarter, adding 11,956 shares for a total of 132,641 shares valued at approximately $19.3 million. Institutional investors and hedge funds collectively own 76.07% of MRK.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $151.32. Merck reported quarterly revenue of $16.61 billion, exceeding estimates, while revenue grew 5.1% year over year.
• Merck pays a quarterly dividend of $0.85, equivalent to a 2.4% yield, but faces risks including insider selling, upcoming generic competition from patent expirations, and a European injunction blocking its subcutaneous Keytruda formulation.

Farther Finance Advisors LLC boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 9.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 132,641 shares of the company's stock after buying an additional 11,956 shares during the quarter. Farther Finance Advisors LLC's holdings in Merck & Co., Inc. were worth $19,274,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Susquehanna Fundamental Investments LLC acquired a new position in Merck & Co., Inc. during the second quarter worth $11,470,000. Russell Investments Group Ltd. increased its stake in shares of Merck & Co., Inc. by 2.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company's stock worth $331,931,000 after acquiring an additional 51,393 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Merck & Co., Inc. by 7.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company's stock worth $794,577,000 after acquiring an additional 402,011 shares during the last quarter. Talon Private Wealth LLC purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter worth $995,000. Finally, Panagora Asset Management Inc. raised its holdings in shares of Merck & Co., Inc. by 410.5% during the 4th quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company's stock worth $74,255,000 after acquiring an additional 567,249 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MRK. Wells Fargo & Company upped their price objective on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an "overweight" rating in a report on Friday, September 4th. TD Cowen boosted their target price on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the company a "hold" rating in a report on Wednesday, September 23rd. Leerink Partners boosted their target price on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the company an "outperform" rating in a report on Wednesday, September 9th. Rothschild & Co Redburn increased their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a "buy" rating in a research note on Monday, July 6th. Finally, BMO Capital Markets raised their price target on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a report on Thursday, August 20th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $151.32.

Merck & Co., Inc. Stock Down 0.2%

Shares of MRK opened at $142.45 on Friday. The company's 50-day moving average price is $143.59 and its 200 day moving average price is $128.16. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The firm has a market cap of $351.45 billion, a P/E ratio of 113.96, a price-to-earnings-growth ratio of 6.42 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.'s revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 2.67 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.4%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is 272.00%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved WELIREG plus LENVIMA for adults with advanced renal cell carcinoma previously treated with a PD-1/PD-L1 inhibitor. The decision expands Merck’s oncology portfolio and could create another commercial opportunity beyond Keytruda. Merck also started a first-in-human trial using Cyprumed’s oral peptide-delivery platform, although that program remains at a very early stage. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Morgan Stanley maintained an “overweight” rating while trimming its price target modestly to $177, implying substantial upside based on the referenced price. The call indicates continued confidence in Merck’s long-term earnings and pipeline prospects. Morgan Stanley Raises Merck Analyst View
• Positive Sentiment: Merck’s shareholder dividend was highlighted as part of its income appeal, which may support investor interest while the company navigates product-cycle and patent risks. Merck Dividend Payment
• Neutral Sentiment: Cantor Fitzgerald raised its price target to $145 but retained a “neutral” rating, suggesting limited near-term upside and a cautious view of Merck’s growth outlook. Cantor Fitzgerald Merck Price Target
• Neutral Sentiment: Articles comparing Innoviva and Merck frame MRK as a large-cap pharmaceutical value candidate, but provide no new company-specific catalyst likely to materially change the stock’s valuation today. INVA vs. MRK: Which Stock Is the Better Value Option?
• Negative Sentiment: A Dutch court granted Halozyme an injunction blocking Merck’s subcutaneous Keytruda in eight European markets. The ruling could delay or restrict commercialization of a potentially more convenient Keytruda formulation and heightens litigation risk. Halozyme Wins Court Order Blocking Merck’s Keytruda SC in Europe
• Negative Sentiment: Industry analysis identifies Merck as particularly exposed to near-term generic competition as major products approach patent losses. That raises concerns about revenue durability and increases the importance of successful launches such as WELIREG. Pharma’s $500 Billion Patent Problem

Insider Buying and Selling

In other news, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company's stock, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Williams sold 52,847 shares of the business's stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock valued at $29,977,783 over the last quarter. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.